单纯放疗与同步放化疗治疗无法手术的食管癌患者的疗效比较

摘要

Objective To explore the survival condition of radiotherapy alone (3D-CRT) and concurrent radiotherapy and chemotherapy for inoperable esophageal cancer.Methods 86 patients who were diagnosed with esophageal cancer were retrospectively analyzed,41 cases received radiotherapy alone was the control group,45 cases received concurrent radiotherapy and chemotherapy was the observation group,the efficacy,survival and incidence of adverse reactions of the 2 groups were compared.Results After treatment,total effective rate of the observation group(91.11％) was significantly higher than the control group (70.73％),the difference was statistically significant (P ＜ 0.05).Within 6 months after treatment,survival rates of the observation group and the control group were 95.5％ and 85.3％,1-year survival rates of the observation group and the control group were 88.9％ and 60.9％,the survival rates in the observation group were significantly higher than the control group,the difference was statistically significant (P ＜ 0.05).During follow-up,66 cases had recurrence and metastasis,which in the observation group was 31 cases (68.89％),the control group has 35 cases (85.36％),and recurrence and metastasis rate differences were statistically significant (P ＜ 0.05).Conclusion Compared to radiotherapy alone,concurrent chemoradiotherapy for inoperable esophageal cancer patients have better outcomes,and be able to improve survival,but it also improves the incidence of adverse reactions such as gastrointestinal reactions,leukopenia,esophagitis.%目的 探究不能手术的食管癌患者采用单纯放疗(3D-CRT)与同步放化疗的生存情况.方法 收集86例食管癌患者,其中由于医疗费用或者家属要求只能采取单纯放疗治疗的患者41例,作为对照组;同步放化疗45例,作为观察组.比较2组的疗效、生存率以及不良反应的发生率.结果 治疗结束后,观察组的总有效率(91.11％)显著高于对照组(70.73％),差异具有统计学意义(P＜0.05).治疗后半年内,观察组和对照组患者的生存率分别为95.5％和85.3％,1年后观察组和对照组患者的生存率分别为88.9％和60.9％,观察组患者的生存率显著高于对照组,差异具有统计学意义(P＜0.05).至随访期满,86例患者中共有66例患者出现复发和转移,其中观察组中有31例(68.89％),对照组中有35例(85.36％),2组复发和转移率差异有统计学意义(P＜0.05).结论 相比较于单纯放疗,同步放化疗治疗不能手术的食管癌患者具有更好的疗效,并能够提高生存率,降低局部复发率和远处转移率.